[{"id":"bc1648bd-c73f-49a2-a8f6-094d16cc301b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05660369","created_at":"2022-12-21T14:58:50.595Z","updated_at":"2024-07-02T16:35:14.877Z","phase":"Phase 1","brief_title":"CARv3-TEAM-E T Cells in Glioblastoma","source_id_and_acronym":"NCT05660369","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","biomarkers":" MGMT","pipe":" | ","alterations":" EGFR amplification • EGFRvIII mutation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARv3-TEAM-E T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/22/2023","start_date":" 03/22/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-03-13"},{"id":"3a17035a-fef8-4bd4-80a2-7c5f2ca1ed3f","acronym":"Intellance1","url":"https://clinicaltrials.gov/study/NCT02573324","created_at":"2021-01-18T12:28:11.635Z","updated_at":"2024-07-02T16:35:48.205Z","phase":"Phase 3","brief_title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","source_id_and_acronym":"NCT02573324 - Intellance1","lead_sponsor":"AbbVie","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 691","initiation":"Initiation: 01/04/2015","start_date":" 01/04/2015","primary_txt":" Primary completion: 04/04/2022","primary_completion_date":" 04/04/2022","study_txt":" Completion: 04/04/2022","study_completion_date":" 04/04/2022","last_update_posted":"2023-05-11"},{"id":"be8c91be-539b-4b14-a9c2-42922b51a31c","acronym":"RTOG Foundation 3508","url":"https://clinicaltrials.gov/study/NCT02343406","created_at":"2021-01-18T11:08:20.656Z","updated_at":"2024-07-02T16:36:44.845Z","phase":"Phase 2","brief_title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","source_id_and_acronym":"NCT02343406 - RTOG Foundation 3508","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 266","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 06/24/2019","primary_completion_date":" 06/24/2019","study_txt":" Completion: 06/24/2019","study_completion_date":" 06/24/2019","last_update_posted":"2020-05-22"},{"id":"b45b7d7e-ea91-4655-9b1a-d36c708995e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123952","created_at":"2021-01-18T15:23:35.910Z","updated_at":"2024-07-02T16:36:58.135Z","phase":"","brief_title":"Expanded Access to ABT-414","source_id_and_acronym":"NCT03123952","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab mafodotin (ABT-414)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-15"}]